Recent Progress in Bioconjugation Strategies for Liposome-Mediated Drug Delivery

DOI Web Site 3 Citations

Description

<jats:p>In nanoparticle (NP)-mediated drug delivery, liposomes are the most widely used drug carrier, and the only NP system currently approved by the FDA for clinical use, owing to their advantageous physicochemical properties and excellent biocompatibility. Recent advances in liposome technology have been focused on bioconjugation strategies to improve drug loading, targeting, and overall efficacy. In this review, we highlight recent literature reports (covering the last five years) focused on bioconjugation strategies for the enhancement of liposome-mediated drug delivery. These advances encompass the improvement of drug loading/incorporation and the specific targeting of liposomes to the site of interest/drug action. We conclude with a section highlighting the role of bioconjugation strategies in liposome systems currently being evaluated for clinical use and a forward-looking discussion of the field of liposomal drug delivery.</jats:p>

Journal

  • Molecules

    Molecules 25 (23), 5672-, 2020-12-01

    MDPI AG

Citations (3)*help

See more

Details 詳細情報について

Report a problem

Back to top